PTO/SB/30 (07-06) Approved for use through 09/30/2006, OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond	U.S. Patent and Trademark Office: I	through 09/30/2006. OMB 0651-0031 J.S. DEPARTMENT OF COMMERCE displays a valid OMB control number.
Request	Application Number	09/371,692
For Continued Examination (RCE)	Filing Date	8/10/1999
Transmittal Address to: Mail Stop RGE Commissioner for Patents P.O. Box 1450	First Named Inventor	Swarn S. Kalsi
	Art Unit	2834
	Examiner Name	Burton S Mullins
Alexandria, VA 22313-1450	Attorney Docket Number	30020-082001
This is a Request for Continued Examination (RCE) under 37 C Request for Continued Examination (RCE) practice under 37 CFR June 8, 1995, or to any design application. See Instruction Sheet for	1.114 does not apply to any uti	lity or plant application filed prior to
Submission required under 37 C.F.R. 1.114 Note: amendments and amendments enclosed with the RCE will	If the RCE is proper, any prev be entered in the order in which	iously filed unentered n they were filed unless applicant

amendments and amendments enclosed with the RCE will be entered in the order in which they were filled unless applicant instructs otherwise. It applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).					
a. \(\subseteq \) Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.					
 i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on ii. \times Other Response to Office Action filed on July 3, 2008 (copy enclosed) 					
b X Enclosed					
i. Amendment/Reply iii. Information Disclosure Statement (IDS) iii Affidavit(s)/Declaration(s) iv. Other					
2. Miscellaneous					
Suspension of action on the above-identified application is requested under 37 C.F.R. 1.103(c) for a period ofmonths. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. 1.17(i) required)					
b. Other					
The RCE fee under 37 C.F.R. 1.17(e) is required by 37 C.F.R. 1.114 when the RCE is filed.					
a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 50-4189. I have enclosed a duplicate copy of this sheet.					
i. RCE fee required under 37 C.F.R. 1.17(e)					
ii. Extension of time fee (37 C.F.R. 1.136 and 1.17)					
iii.					
b. Check in the amount of \$ enclosed					
c. Payment by credit card (Form PTO-2038 enclosed)					
ARNING: Information on this form may become public. Credit card information should not be included on this form.					

WARNING: Information on this form may become public. Credit card information should not be included on this form Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Signature	Frak R. Oulil	Date	July 22, 2008	
Name (Print /Type)	Frank R. Occhiuti	Registration No.	35,306	

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United Statos Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Falent and Trademark Onice on the date shown below.						
Signature						
Name (Print /Type)		Date				

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to fits (and by the USPTO to proceed) an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggesterions for reducing the burden, should be sent to the Charl Britishney of Charles and Trademark Office, U.S. Patient and Trademark